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Introduction 1
Despite many improvements in Cardiac Arrest (CA) management, survival rate ranges from 2 11 to 17% [1, 2] . Among CA patients who survived initial resuscitation, less than 30% 3 survived to hospital discharge [3] [4] [5] . Post Cardiac Arrest shock (PCAS), defined as the 4 association of a myocardial dysfunction and vasoplegia occurring after return on 5 spontaneous circulation (ROSC) [6] , is globally responsible of one-third of deaths [5] . While 6 persistence of myocardial dysfunction at 24h may be associated with early death [7] , no 7 differences in neurological outcomes have been shown between post-CA patients with PCAS 8 and those without PCAS [5, 7] . 9
Recently, two studies have described the use of Extracorporeal Life Support (ECLS) in 10 successfully resuscitated CA patients experiencing severe PCAS [8, 9] . Although survival 11 benefit was not demonstrated, ECLS-assisted patients had acceptable neurological 12 prognosis. A solid understanding of key governing factors that lead those patients to die are 13 thus requested to better select the patients the most likely to benefit for this strategy. 14 Our objectives were 1/ to describe a cohort of PCAS patients treated with ECLS and 2/ to 15 identify factors that lead physicians to indicate initiation of ECLS in post-CA patients. 16 17
Material and Methods 18

Population and Data collection: 19
This retrospective observational study was conducted in two tertiary university centers in 20 Paris. We included consecutive patients admitted to intensive care unit (ICU) for CA and 21 PCAS (defined as the need for continuous norepinephrine or epinephrine infusion to maintain 22 mean arterial pressure above 60 mmHg for more than 6 hours following restoration of ROSC 23 despite adequate fluid loading [5] ), and for whom an ECLS was initiated. Patients with 24 refractory CA and in-hospital CA (except those that occurred in the cath-lab and the 1 emergency ward) were not included. 2 ECLS-treated patients' data were collected retrospectively. Prospective database 3 implemented in Cochin Hospital was used to identify control group of patients experiencing 4 PCAS without ECLS [2] . 5
Our local ethics committees approved the data collection and study protocol . 7
Treatment protocol 8
Patients admitted for CA were treated according to international guidelines, and similar 9
procedures have been described elsewhere [2, 10] . ECLS implantation and patient's 10 management during ECLS support, including anticoagulant treatment or weaning procedure 11 followed ELSO guidelines [12] and were previously described [11] . 12
Neurological outcome was daily assessed by ICU physicians, until death or ICU discharge. 13
According to guidelines [13] [14] [15] [16] , neuroprognostication was performed daily using a 14 multimodal approach, and life-sustaining therapies withdrawal decision was taken during a 15 collegial consultation. 16
Outcomes 17
The primary outcome was the neurological evolution at one year, assessed by the Cerebral 18
Performance Category [17] (Favorable Outcome : CPC score = I -II ; Poor Outcome: CPC 19 score = III -V) [18] at 1 year. 20
Analysis 21
We performed a description of factors associated with unfavorable neurologic outcomes at 22 one year in the population of PCAS patients treated with ECLS. A logistic regression was 23 performed to assess the association between the selected variables and the neurological 24 outcome. ECLS group was compared with control group, using two-sided t test, or chi 2 test 1 when necessary. Finally, we performed a univariate and multivariate analysis, using a 2 stepwise logistic regression, to identify factors associated with the ECLS implantation. 3
Results are expressed as median (interquartiles 25-75) Three patients were non-included because of in-Hospital CA. Among the 3 patients non-10 included, one was admitted for septic shock consecutive to a pulmonary infection, the CA 11 occured 8 days after the admission, and the patient deceased. One patient was a severely 12 burned patient with ARDS. He deceased 17 days after his admission while on ECLS for CA 13 consecutive to pulmonary embolism occurring 14 days after his admission. The last non-14 included patient was admitted for intoxication with beta-blockers, the ECLS being inserted 5 15 days after his admission, for extreme hemodynamic instability, he died while on ECLS. 16
Finally, 43 patients fulfilled the inclusion criteria. We also include a control population 17 composed by 878 PCAS patients. ECLS population was predominantly young males, with a 18 previous history of coronary events ( Death rate during the ICU stay (79%) was mainly related to multiple organ failure (MOF) 1 (63%). Forty-five percent of death by MOF occurred in the first three days after ICU 2 admission ( Figure 1 ). ECLS inefficacy, defined as the inability to maintain cardiac output and 3 arterial pressure despite maximal therapeutic investment, was observed in 11 of deceased 4 patients (31%). Life-sustaining therapy withdrawal was initiated for 9 of them (26%), and 5 cerebral brain death was pronounced for 2 patients (6%). 6
No statistical difference was found between centers except for the percentage of bystander 7 CPR and Low-Flow duration (Table S1 ). 8 ECLS-treated patients who survived without severe neurological disability were younger than 9 those with severe neurological impairment (Table 1) . CPR characteristics and severity scores 10 were not different between the favorable and the poor neurological outcome group, despite 11 OHCA score showed a trend toward higher values in poor neurological group. By contrast, 12 blood lactate level at ECLS implantation discriminated the two groups (Table 2 and figure 13 S1). Coronary etiology of CA was associated with unfavorable outcome at one year, whereas 14 the arrhythmia was associated with a better prognosis (Table 1) . 15 ECLS-treated patients were younger, with a longer time to ROSC and a higher proportion of 16 non-public location of CA and bystanded CPR, as compared to control group (Table 3) . 17 ECLS-treated patients had higher blood lactate and creatinine levels than the control. 18
In multivariate analysis (Figure 2 ), factors independently associated with ECLS implantation 19 were as follows: age < 62 years old, serum creatinine > 109 µmol/l, administration of 20 adrenaline < 2 mg, and public location of CA. 21
When considering the whole PCAS population, non-survivors at ICU discharge were older 22 and experienced higher blood lactate and serum creatinine levels (Table 4 ). Time to ROSC 23 were longer when comparing non-survivors to survivors. The etiology for CA in survivors was 24 predominantly cardiac, with higher rates of coronary angioplasty. The proportion of ECLS-25 treated patients was not different in survivors versus non-survivors. 26 1
Conclusions Discussion 2
Emphasizing on functional neurological outcomes, this observational study offers interesting 3
findings. 4
The present retrospective study aimed at reporting the ten-year experience of two Parisian 5 intensive care units in the application of ECLS for PCAS patients. Even though the death rate 6 was high, the survivors of ECLS-treated PCAS population exerted no or minor neurological 7
disabilities. Furthermore, the death rate in the ECLS-treated population is of a magnitude of 8 the death rate of the PCAS population, although the severity was higher in the first 9 population as compared to the second. The latter observation might raise the question of the 10 potential benefit of ECLS in such a severe population. It also highlights the need for better 11 identification of patients who could benefit of such investment. Therefore, we have identified 12 blood lactates level at ECLS implantation and reversible cause of OHCA as potential factors 13 associated with better outcomes. 14 In the survivors of ECLS-treated PCAS population, the potential for recovery of neurological 15 function was high (89% of surviving patients were alive without severe neurological 16 impairment). These data are consistent with previously published data [5, 7] , although ECLS 17 wasn't used in those latter studies. Faster time to implantation could be a particular endpoint 18 to achieve, as suggested by available data in the setting of refractory cardiogenic shock [19] . 19
Well-designed studies are lacking to support this hypothesis in the setting of PCAS. On the 20 contrary, selecting patients the most likely to benefit for such a therapy could improve 21 functional outcomes. Indeed, despite we observed that the mortality was not significantly 22 different in the ECLS-treated population as compared to the control, blood lactate level, as 23 well as the etiology of CA, was associated with neurological outcomes. Initiating ECLS on 24 patients with low blood lactate level, and suffering for PCAS consecutive to reversible cause, 25 could improve survival rates. Indeed, even though Bougouin et al. [9] showed no association 26 between ECLS implantation and survival, our study suggests that the coronary etiology could 27 be a potential confounding factor. Reversible causes of myocardial dysfunction could then 1 have a better prognosis in terms of myocardial recovery [20] . By contrast, in case of 2 constituted myocardial infarct, the potential for recovery could be altered [21] [22] [23] . In fact, 3 mortality observed in patients treated with ECLS for PCAS secondary to acute coronary 4 syndrome, was higher than mortality observed in patients treated with ECLS for reversible 5 causes. The mortality rates observed in our study remained high, but were comparable to 6 those reported in the two previously published studies, respectively 72 [8] and 73% [9] . 7
Complications occurred frequently, but were close to those reported in a meta-analysis of 20 8 studies evaluating ECLS usage [24] . The most frequent complication in our study was acute 9 kidney injury requesting renal replacement therapy (50%), being probably more a marker of 10 the severity of the shock rather than a specific complication of ECLS. On the contrary, the 11 high rates of specific complications of ECLS observed in our cohort, as the rate of lower limb 12 ischemia (28% versus 17% in Cheng's study [24] ), could worsened the prognosis of some 13 patients. However, ECLS implantation was performed by physicians trained to percutaneous 14 cannulation with previously published good results [11] . 15
The retrospective design of the study limits the strength of the findings. We focused on a 16 specific subpopulation of PCAS patients, and we retrieved data from 10 years' experience of 17 two tertiary care centers. No randomized study could have been achievable in a reasonable 18 time-frame. A matched analysis designed to identify the variables associated with survival 19 would have been useful, but the low sample size of the ECLS cohort, as well as the particular 20 severity of these patients have prevented us to conduct such a matching. Moreover, we were 21 unable to collect information regarding severity at admission in the control population. 22
We limited the inclusion to the patients admitted for OHCA on purpose, even though the 23 outcomes of the 3 patients non-included could have influenced the overall results of this 24 study. Indeed, OHCA is a sudden and life-threatening pathology for whom the delay for 25 initiation of the treatments is a key aspect of the prognosis. In-Hospital CA is a more 26 heterogeneous entity, where pre-existing life-threatening pathology leads to CA. The 1 prognosis of the CA should be the combination of the pre-existing condition and the CA by 2 itself. It would have been difficult to conclude on the ECLS intervention, because of this 3 heterogeneity. 4 5
Conclusion 6
Despite high rate of death in the ECLS-treated population, the neurological outcomes of the 7 survivors suggest a potential beneficial effect of ECLS on neurological recovery and justify its 8 implantation for extremely severe population, as a salvage therapy. While ECLS initiation, 9
reported in this present work, does not impact mortality, neurologic outcomes of survivors 10 suggest a potential beneficial effect on neurological recovery. The neurological evolution 11 could be more likely related to the initial brain injury, rather than the PCAS by itself. 12
Furthermore, Reversible etiologies of cardiac arrest were associated with better outcomes, 13 emphasizing on selection of patients who could benefit of such a therapy. Considering the 14 assistance only for patients for whom the myocardial depression has the potential to recover 15 could be an interesting option to improve outcomes. Assistances ECMO n (%) 9 (4) 34 (5) 
